Aim of the study: A functional classi®cation of treatments for erectile dysfunction is important but none exists at present. Advances in the understanding of the mechanisms of drug action and of the mechanisms of penile erection suggest that there is now a rational basis for a therapeutic classi®cation, with the expectation that a logical diagnostic classi®cation will follow.
Introduction

Taxonomy
1 is an exercise with a honorable tradition and is a discipline that is badly needed to sort out the confusing array of treatments that are now available for erectile dysfunction. Historically, before scientists could explain much about the details of the natural world they became avid recorders and classi®ers of what they could see. 2, 3 This exercise in classi®cation, although possibly appearing to be pedantic, can greatly assist in understanding the principles of a discipline. Classi®cation can become very important when it can guide treatment by establishing therapeutic intent and predicting outcomes. In addition, it will provide a context for a true comparison of the outcomes of treatments using drugs in a similar care. Further, the appropriate classi®cation of even complicated therapies will make it possible to create a new more precise, and clinically meaningful, diagnostic classi®cation (namely, the ef®cacy of the therapeutic agent can become the basis for diagnosis).
The treatment of erectile dysfunction (ED), at the end of the 1990s, is poised to expand rapidly and widely in the next few years. Existing approved therapies are limited in number. They can be listed individually with good con®dence that their characteristics are identi®able and their actions selfexplanatory. 4 However, the speci®c mechanisms of action that underlie these therapies were not fully understood. Interestingly subsequent research has shown that some of the early concepts used to explain the effect of different agents were almost visionary in their insight. For instance, the use of intracavernous agents is a model of direct local intervention in cellular processes 5 although the full details of the mechanisms of action were not known originally. The science has advanced and clinicians today are faced with applying drugs with pharmacological properties of increasing complexity. For instance, the clinical use of agents which modify second messenger pathways, such as phosphodiesterase inhibitors, is just around the corner.
The transition from compounds of interest in research to the development of prescription drug is not necessarily more rapid or more logical now but it is surely more frequent. This situation re¯ects the growth of the drug industry as a whole in terms of its interest in the ®eld of erectile function as well as the growth of the appetite of the consumers (the patients and the doctors) for better products. In addition there appears to be a general trend away from choosing invasive surgical solutions. The clinical context of the diagnosis and treatment of ED has changed radically. As a result, ED will become a condition managed medically with increasing sophistication.
We are now entering an era of enhanced selectivity of compounds which will likely enable a more precise diagnosis and a choice of more speci®c therapy. Therefore, we need a language to describe where the current and future agents can be`®tted' based on rational therapeutic objectives. It is no longer enough to say that`your erections will get better with this' or to assume that the sledgehammer one needle suits all' is optimal therapy.
The paper details a practical classi®cation based on currently used and proposed treatments and their putative mechanisms of action.
Methods
We reviewed the currently accepted range of therapeutic options detailed in the recent AUA guidelines on treatment. 4 The recent meeting of the International Society for Impotence Research afforded an opportunity to record the more important new therapies and these have been included where possible. Other signi®cant therapies, widely known to be in development or reported at meetings were also considered. The modalities were all assessed for their most prominent, or claimed, mechanism of action when delivered as intended.
This ®rst assessment suggested a classi®cation into ®ve broad categories of treatment. It also revealed the importance of identifying two other properties of treatments, the routes of delivery and the means of achieving selectivity in the intended target organ or system (for example, why should an oral agent selectively affect smooth muscle in the penis?). The classi®cation therefore details a primary class (Mode of action) and two necessary subsets (intended route of delivery, mechanism of selectivity). The primary class indicates a mode of action in contrast to a speci®c mechanism of action. Thus, this classi®cation recognizes that different mechanisms of action can result in identical modes of action.
Results
This analysis is restricted to the three dimensions: mode of action, route of delivery and mechanism of speci®city. Table 1 lists the suggested classes and available subsets.
See Table 2 for an explanation of the suggested classi®cation by mode of action for treatments of erectile dysfunction.
The principles of the proposed classi®cation can be developed and may be found in Table 3 with actual examples.
When the use of this basic classi®cation does not capture the important mechanisms of a speci®c site this point should be clari®ed. For example, a ®ctitious new`highly selective vasodilator' analogue has been devised for oral use. It is marketed as a tablet to be taken situationally. The speci®city of the oral compound comes from the fact that it is given immediately before the need for erection not from any biological properties or formulation techniques. If such a product were administered it would have general vasodilator effects wherever there were functional`highly selective vasodilator' receptor systems. To claim and identify special site speci®c activity for such a compound would be inaccurate. However, in another hypothetical scenario, if highly selective vasodilator' receptors in the penis were proven to be activated by this analogue at concentrations 2 log units below those required to activate`highly selective vasodilator' mechanisms elsewhere (namely, numbers of effectors per cell) and the drug was engineered to deliver serum levels only rising high enough to affect the penile`highly selective vasodilator' receptor systems speci®cally, the drug could justly be described as an oral preparation with selectivity due to density of receptors in a speci®c location.
Discussion
There is no functional classi®cation of drugs for ED. The AUA guidelines on treatment explain well what is available today although they do not consider the area of hormonal supplementation. However, the increase in number of potential new therapies brings a real need to classify agents in order that treatments can be compared and used in a rational manner. There is no`Gold Standard' therapy for ED to use as a bench mark because there are numerous etiologies for ED and patient choice has such a large part to play in identifying a successful treatment. At present there is not even an established understanding of how to classify ED although some attempts have been made. In setting out a new schema for therapeutic classi®cation, as it is proposed here, it is important to look to the past and the future. The classi®cation of therapies in other disciplines, such as antihypertensive agents, provide a useful case study based on past experience. The future of a good system of classi®cation is that it will evolve into a widely used and clarifying nomenclature. The system should provide a basis by which new therapies can be easily assigned and Compounds that act mainly to improve the local or systemic internal milieu so that penile erection is enabled or enhanced V Other Other ways of promoting penile rigidity including devices and surgery should give rise to a practical diagnostic classi®ca-tion. The everyday classi®cation of antihypertensive agents provides a model of features to follow and ones to avoid. Antihypertensives share the common goal of reducing blood pressure (BP) which is an easily identi®ed and measured outcome. There are, however, many quite different modes of action with a wide variety of mechanisms of action that can induce lowering of BP. Although this diversity is known, antihypertensives have been subcategorized predominantly by their speci®c mechanisms of action as opposed to categorizing by the mode of action that lowers BP. For example, two drug classes both of which modify blood volume include the diuretics and angiotensin converting enzyme inhibitors (ACEI). They are actually different in how they achieve blood volume changes; one by modifying sodium resorption from the ascending limb and distal tubules and the latter by decreasing the levels of a hormone system involved in active reabsorption. Pharmacologically these are in different classes and this is what governs their designation within the ®eld of antihypertensives. This is despite the fact that the clinical use of such drugs, alone and in combination, should be guided in part by their clinical action in modifying blood volume. Further, bioavailability, onset and duration of action, and required frequency of use all will vary according to the particular routes of administration and the particular formulations used and although not well understood the proposed differences are heavily marketed.
Similarly, the usual goal in the management of ED is to restore erections and improve the quality of life. But, it is necessary that these objectives are achieved using a method that is acceptable to the patient and, often, his partner. So, in managing ED we do not necessarily have penile rigidity, at any cost, as the universal therapeutic goal. This is a less well de®ned end point than is the case in achieving a lowering of blood pressure. Further, we are compromised by our inability to (a) identify standards or normals and (b) classify the causes of the loss of erection. Without standard diagnostic or therapeutic methods, or classi®cations, it is dif®cult to compare patients and drugs, and dif®cult to target the speci®c de®ciencies causing ED.
The uncertainty about diagnostic classi®cations probably explains why the controversy over what constitutes`psychogenic impotence' rages so freely. It is not a single condition. There is not a unique set of measurable characteristics. There is not a universally successful means of achieving penile rigidity (except by mechanical means, for example, penile prosthesis or vacuum erection device). Most physicians experienced in the management of ED can probably identify men they would like to call purely psychogenic', but they still can not diagnose or treat the problem with any ®nesse. This is probably because psychogenic impotence is caused by a multitude of biochemical changes in the brain that in turn interact with the neuronal mediation of normal erectile function at multiple levels. This would all become much clearer if an effective drug, with known and speci®c mechanisms from a given Class were found to improve a fraction of this otherwise vague group. A group of men would be de®ned by their successful treatment and the treatment would probably become a diagnostic test. Further, it would then be reasonable to classify the etiology of this group of men by their ability to respond to this drug. This may be the most useful means of achieving a diagnostic classi®cation scheme as it is based on the ability to identify an effective therapeutic entity.
A separate analogy of classi®cation comes from cardiovascular pharmacology. The advent of selective agonists and antagonists for even sub-types of adrenoceptors has, in large part, allowed these receptor systems to be mapped and analyzed in man. These selective drugs can be used in a logical way, to de®ne the tissues and their adrenoceptor content and the seci®city of action. In other words, classical pharmacological analysis is based on linking drug mechanism of actions and the resulting effects to provide an empirical basis for de®ning a role for a given receptor system. So will it be in ED. If we keep the sites and mechanisms of drug action ®rmly in view as we study and use these agents we will be able to build better de®nitions of the dysfunction, and hence the therapeutic needs, within the heterogeneity that is ED. The speci®city of the drugs will permit functional classi®cations of ED subtypes. These classi®-cations will be amenable to speci®c diagnosis and targetted treatment. As this increase in precision reaches clinical practice the clinical outcomes will improve and the adverse components of treatment will decrease. We already do not have to place a penile prosthesis in penises that respond to PGE1. We will, in the future, be able to treat some men with oral agents targetted, say, to their inability to initiate an erection. Not only will these men not have to be injected but we will then know how to classify them diagnostically. We will be able logically to select from a range of therapeutic agents once we have a therapeutic classi®cation.
But, in linking knowledge of therapeutic mechanisms and classi®cation with diagnostic and etiological issues it is necessary to sound a note of caution. A positive response to a drug does not mean that the drug is needed for erection. If there is an understanding of the selectivity of a drug, and therefore of its mechanism of action in producing an erection, this drug can be used therapeutically and it can provide us with some information about the etiology of the ED. If a compound does not work in a man with ED you can argue certain things about the pathophysiology of his disease. The converse is not always true, if a treatment works to produce an erection it does not necessarily say much about the cause of the ED. For example, PGE1 by intracavernous administration will cause an erection 70% of the time, 7 but it does not mean that the ED was caused by a lack of PGE1 or any defect at all in the penis. Again, if nocturnal penile tumescence (NPT) occurs during sleep it simply identi®es that the system has the capacity to generate an erection under certain circumstances, it does not point with certainty to the pathophysiology of the ED.
Evolving a therapeutic classi®cation for ED forces the need to look at the many systems that contribute to erectile function. It is interesting to look back at the un¯attering view of ED that pertained before the 1970s. ED was a wasteland, a ®eld of little importance, and all problems were said to be`in your head'. See Figure 1 , As treatments came available for the penis an increasingly penocentric view of ED took hold. Whether consciously or not, there developed a search for a silver bullet for ED based on the notion that a single powerful solution would solve most clinical ED. The present`age of enlightenment' will probably be as de®cient as these previous views in a short time but for now it is helpful to think of the multiple and overlapping contributing systems. It is this complexity of the interacting systems that contribute to erectile function which makes classi®cation so important.
The classi®cation suggested in this paper hinges on the identi®cation of two main characteristics. Firstly, there is a fundamental practical difference between initiating an erection (initiators) and helping an erection already under way (conditioners). Secondly, there are different implications for sideeffects and drug delivery that arise from targetting central or systemic processes. Then there are the other treatments that are peculiar to ED like prostheses and vacuum devices that need to be accommodated in a special class.
Initiators have quite different implications for the timing of therapy when compared with conditioners, the words may not be perfect but the implications are fairly clear. Initiators will provoke a process, which if successful, will create an erection. Conditioners change anatomic cellular or molecular systems so that when a signal for tumescence arrives it will facilitate the generation of an erection. A combination of an initiator and one or more conditioners is obviously logical. A combination of conditioners may be logical if the mechanisms of action are compatible. Combinations of central initiators may be more problematic unless enough is known about the exact time pro®les of activity and the pattern of neuronal activation. Overall, such a classi®cation will permit or even suggest logical combinations of treatments in certain situations when there are two or more etiologies coexisting to cause ED in an individual or when there are two or more complementary therapeutic strategies that can be employed for a particular etiology (for example, situational ED could be treated with an initiator and a conditioner).
Initiators will tend to work by causing some cellular systems to reach a threshold of activity which will result in a cascade of events. Conditioners may change the gain of those events. For instance, a medium size artery in a sympathetically activated (for example, stressed) man will probably be more tonically constricted than in ideal circumstances. Antagonizing some of the`extra' constrictor tone may permit a standard vasodilator (erectile) signal to achieve a better level of smooth muscle relaxation. The vessel has been`conditioned' to enhance the gain of the vasodilator stimulus. In some circumstances deciding how to classify drugs may not be obvious. It will be necessary to apply the best current understanding of the mechanism of action of the drug. It will be expected that some drugs will require reclassi®cation. Apomorphine affects dopamine receptors wherever they are. It happens to produce meaningful activity only in neurons in the brain at a concentration many hundreds of times less than is required for measurable effects on, say, small arteries. This margin of selective activity is so large that at very low concentrations any observed activity in causing erection can reasonably be said to result from selective activity in the brain. Hence apomorphine is classi®ed as a selective central initiator.
Phosophodiesterase (PDE) enzymes are ubiquitous. There is a substantial amount of type V in the penile and other arteries (for example, coronary). 17 A phosophodiesterase inhibitor (PDEI) may have an af®nity many times greater for the type V isozyme. That PDEI will have a selective effect on processes dominated by type V phosophodiesterases and may be considered moderately penile selective only if the other effects (vascular, cardiac, retinal, platelet, etc), caused by a similar mechanism, are less sensitive. 18 Because PDEI only have a visible effect when there has been activation of the signal transduction pathway the drug can be said to condition the system. Thus a PDEI type V may be classi®ed as a perpheral conditioner with selectivity which depends on the dose required to affect penile tissue more than other tissues.
Testosterone has effects in growth and regulation throughout the body. It is not known how much of the effect the altered androgen milieu has on erectile function derives from action in the brain and how much derives from peripheral effects, say, on nitric oxide synthase in the penis. It is a conditioner, but it would be pure speculation to say clearly that either the central or peripheral effect was more important. Testosterone is clearly speci®c for the testosterone receptors but not at all speci®c in which cellular processes these receptors are linked to.
It is possible to analyze all known treatments using this framework but space here is limited. The principles should be suf®cient to guide knowledgeable specialists to similar conclusions about the same drug. The classi®cation proposed should be modi®ed as is necessary to create meaningful and useful classes of drugs. Eventually, this or better systems will help investigators de®ne treatments and then diagnostic groupings. As the specialty matures around such endeavours the national regulatory bodies will ®nd it easier to understand and regulate how new drugs ®t in, how they should be evaluated, what the reasonable equivalences are among agents, and in whom these drugs and devices should eventually be used.
Conclusions
This paper details a new basis for classifying treatments for erectile dysfunction. The reasons for needing such a scheme relate to the imperative to de®ne basic issues in the mechanism of drug action and treatment equivalencies for clinical purposes. A classi®cation scheme for treatments will naturally lead to better understanding of the outcomes of treatment and how patients stratify in their responses to different classes of drugs. From such information will emerge a rational basis for de®ning a diagnostic classi®cation.
New treatments emerge from progress in basic scienti®c understanding. Basic mechanisms in health and disease are inextricably linked with clinical presentation. The clinical presentation provides the clues for recommending speci®c therapies. In turn those therapies need updating and improving and the circle is closed. We have so far been unable to de®ne a diagnostic classi®cation that is functional and durable. The understanding of the mechanisms of drug action and of the mechanisms of penile erection is now suf®ciently advanced that it is reasonable to attempt a therapeutic classi®cation with the expectation that a logical diagnostic classi®cation will follow. Thus armed we will be better equipped to embrace the new therapies for erectile dysfunction and apply them logically to further enhance patient outcomes. It is our conclusion that with such endeavours the specialty itself and national regulatory bodies will ®nd it easier to de®ne and control how to apply new drugs, how to evaluate new drugs, and how to establish reasonable equivalences among agents and in whom these drugs and devices should be used.
